CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Friday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Down 4.2 %

CEL-SCI stock opened at $0.26 on Friday. CEL-SCI has a fifty-two week low of $0.25 and a fifty-two week high of $2.39. The stock has a market cap of $20.08 million, a PE ratio of -0.54 and a beta of 0.67. The firm’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $0.65. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after purchasing an additional 53,879 shares during the last quarter. Thoroughbred Financial Services LLC raised its position in CEL-SCI by 40.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after acquiring an additional 54,900 shares during the period. Finally, Plotkin Financial Advisors LLC bought a new stake in CEL-SCI in the third quarter worth about $98,000. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.